In the present study, we investigated the different types of neocortical rhythmic slow activity (RSA) during wakefulness and paradoxical sleep as well as their pharmacological modification. During wakefulness, the high-frequency (7-9 Hz) RSA1 type, which is atropine-resistant, is accentuated by forebrain stimulation and is abolished by urethane, clonidine and alcuronium. These drugs induce the...
From the stembark of Tabernaemontana crassa the alkaloid ibogaine was isolated as the major component. Ibogaine showed activity against the gram-positive Bacillus subtilis. Conopharyngine was identified as one of the minor compounds.
More than 200 species and/or varieties of higher plants, as well as numerous species of basidiomycetes, are reported in the literature to have been used for their hallucinatory and/or euphoriant effects.Due to a paucity of research, only a few of these have been confirmed as definitely hallucinogenic in man or animals.This article reviews all of those plants now known to have a scientific basis...
Ethanol extracts of Ervatamia orientalis have yielded the following known alkaloids: ibogaine, iboxygaine, voacristine, vobasine, dregamine, tabernaemontanine, apparicine, voacamine and 16- demethoxycarbonylvoacamine. In addition, two new dimeric alkaloids of the voacamine group and the novel 2-acylindoles ervatamine, 20- epiervatamine and 19-dehydroervatamine have been isolated from the...
The action of JB-336, psilocybin, ibogaine and bufotenine on the aggressiveness os isolated mice, as well as the muricide reaction of rats, was investigated. All drugs evoked a substantial decrease in aggressiveness, but this effect was dependent on isolation time, time after injection and the type of test used.
Our use of drug-facilitated psychotherapy has been to aid repressed material to become conscious and to increase insight. Any method or tool which facilitates these processes has the possibility of being a valuable psychotherapeutic tool. Certain drugs on which we have done research, such as mescaline, ALD-52, ibogaine, psilocybin, Ditran (N-ethyl-3-piperidyl cyclopentylphenyl glycolate HC1),...
Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including those that are treatment-resistent. The latter half of the 20th century marked a revolution in the treatment of mental illnesses, exemplified by the introduction of selective serotonin reuptake inhibitors and other...
Psychedelic therapies—ketamine, MDMA, psilocybin, LSD, DMT, and ibogaine—are moving from prohibition to regulated care, but commercialization hinges on FDA approval, DEA scheduling, and payor (insurance) coverage. This Article maps the U.S. regulatory labyrinth and analyzes how business models succeed or fail under these constraints. It explains bifurcated rescheduling (DEA reschedules the...
Clinical trials for novel therapeutics are extraordinarily expensive, and psychedelicassisted therapies pose a particular financing challenge: the underlying compounds (MDMA, psilocybin, LSD, ibogaine) are off-patent or unpatentable, limiting the traditional commercial incentives that fund late-stage drug development. This essay examines an emerging alternative-the "pseudo-nonprofit" financing...